✨ Free AI Report
Vistin Pharma ASA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Vistin Pharma ASA
Company Research

Vistin Pharma ASA: Business Overview, Financials & Competitive Analysis

Vistin Pharma ASA scores 7/10 on the AskCyborg Cyborg Score (Strong). Focused pharmaceutical ingredients player capturing growing global diabetes market with strong balance sheet and unique European supply positioning. Vistin benefits from a unique market position as Europe's sole dedicated Metformin producer in a growing diabetes treatment market. Strong financial fundamentals with 81% equity ratio and consistent revenue growth support.

What is Vistin Pharma ASA's industry? Vistin Pharma ASA (vistin.com) operates in Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing. AskCyborg classifies Vistin Pharma ASA under Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing in its company registry.

Vistin Pharma is Europe's sole dedicated Metformin Hydrochloride (HCl) producer, supplying leading international pharmaceutical companies. The company is doubling its production capacity to supply the growing need for...

7/ 10Strong

Cyborg Score thesis

Focused pharmaceutical ingredients player capturing growing global diabetes market with strong balance sheet and unique European...

Read the full analyst-debate transcript →
Industry Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing
1 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Vistin Pharma ASA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Vistin Pharma ASA

AskCyborg analysts argue the bull and bear cases for Vistin Pharma ASA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Vistin Pharma ASA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Vistin Pharma ASA Overview

Pro stress-test →

Vistin Pharma is Europe's sole dedicated Metformin Hydrochloride (HCl) producer, supplying leading international pharmaceutical companies. The company is doubling its production capacity to supply the growing need for Type 2 diabetes medicine globally.

Strategic Profile

Pro stress-test →

As a well-positioned sole European supplier, Vistin holds a defensible market position with exclusive geographic focus. The company maintains a strong balance sheet with an 81% equity ratio and net cash position. Revenue grew 44% year-over-year to NOK 438 million in 2023, demonstrating robust market demand for diabetes treatments.

Competitive Landscape

Pro stress-test →

Vistin operates in the pharmaceutical active pharmaceutical ingredients (API) market with minimal direct competitors in Europe for Metformin HCl production. Primary competition comes from non-European producers, primarily in Asia. The company's exclusive geographic positioning and FDA-inspected manufacturing facilities provide significant competitive barriers.

Industry Context

Vistin Pharma ASA operates in Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing.

Key facts

Headquarters: Oslo, Norway · Revenue: NOK 438M (2023) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Vistin Pharma ASA.

  • Monopoly-like position as Europe's only dedicated Metformin HCl manufacturer serving international pharma companies
  • Significant capacity expansion underway targeting >7000 MT/year to meet rising Type 2 diabetes treatment demand
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2025Dividend payment of NOK 1.25 per share approved at AGM
  • May 2025Board member Øystein Stray Spetalen withdrew from re-election; Chairman Brøymer increased shareholding to 44.35%
  • +1 moreTrack every material event for Vistin Pharma ASA as it happens. Explore monitoring →
Get alerted when Vistin Pharma ASA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Metformin Hydrochloride APIGlobal Metformin producers based primarily in China and India→

Compare Vistin Pharma ASA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Vistin Pharma ASA operates in Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing research →
NEW · MCP server

Ask your AI assistant about Vistin Pharma ASA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Vistin Pharma ASA and its top competitor on Cyborg Score”
“What did Vistin Pharma ASA do this quarter?”
“Is Vistin Pharma ASA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Vistin Pharma ASA do?+
Vistin Pharma is Europe's sole dedicated Metformin Hydrochloride (HCl) producer, supplying leading international pharmaceutical companies. The company is doubling its production capacity to supply the growing need for...
What is Vistin Pharma ASA's Cyborg Score?+
Vistin Pharma ASA has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Vistin Pharma ASA's main competitors?+
Named competitors include Metformin Hydrochloride API. The full competitive landscape is in the AskCyborg report.
How can I get the full Vistin Pharma ASA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Vistin Pharma ASA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Vistin Pharma ASA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.